Anti-chloride Intracellular Channel Protein 1 (CLIC1) Antibodies Induce Tumour Necrosis and Angiogenesis Inhibition on<i>In Vivo</i>Experimental Models of Human Renal Cancer

Radu-Cosnita, Andrei Dan; Neşiu, Alexandru; Berzava, Patricia Lorena; Cerbu, Simona; Cosma, Andrei; Comşa, Şerban; Sarb, Simona; Ferician, Adela Maria; Ferician, Ovidiu Catalin; Cîmpean, Anca Maria

doi:10.21873/anticanres.15599

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CLIC1 overexpression in tumor cells has recently been identified as a potential angiogenic factor favoring tumor angiogenesis [ 28 ], invasion, and metastasis [ 29 , 30 , 31 ]. Cosnita et al used anti-CLIC1 antibodies to demonstrate CLIC1-expressing tumor cell necrosis and tumor blood vessel inhibition on chick embryo chorioallantoic membrane ccRCC tumor model xenografts [ 32 ]. All 13 papers reporting CLIC1 expression in endothelial cells use only in vitro data [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

The Mutually Mediated Chloride Intracellular Channel Protein 1 (CLIC1) Relationship between Malignant Cells and Tumor Blood Vessel Endothelium Exhibits a Significant Impact on Tumor Angiogenesis, Progression, and Metastasis in Clear Cell Renal Cell Carcinoma (ccRCC)

Ferician

Neşiu

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Background: Overexpression of chloride intracellular channel protein 1 (CLIC1) in tumor cells has been confirmed, but it has received less attention in the tumor blood vessel endothelium. Aim. The assessment of CLIC1 expression in ccRCC tumor blood vessels and its relationship with TNM parameters and tumor cell CLIC1 expression. Methods: CLIC1 immunostaining in ccRCC was evaluated in 50 cases in both malignant cells and tumor blood vessels (CLIC1 microvessel density-CLIC1-MVD) and was correlated with TNM staging parameters. Results: CLIC1-MVD was observed in approximately 65% of cases, and CLIC1 co-localization in both tumor and endothelial cells was observed in 59% of cases. ccRCC was classified into four groups (Classes 0–3) based on the percentage of positive tumor cells, with each group including sub-groups defined by CLIC1 expression in the endothelium. Class 3 (60–100% positive tumor cells) had the highest CLIC1-MVD, with an impact on T and M parameters (p value = 0.007 for T, and p value = 0.006 for M). For cases with CLIC1 intracellular translocation, there was a strong correlation between CLIC1-MVD and M (p value < 0.001). Conclusions. Co-expression of ccRCC tumor and endothelial cells promotes tumor progression and metastasis and should be investigated further as a potential therapeutic target for ccRCC and other human malignancies.

show abstract

Section: Discussionmentioning

confidence: 99%

The Mutually Mediated Chloride Intracellular Channel Protein 1 (CLIC1) Relationship between Malignant Cells and Tumor Blood Vessel Endothelium Exhibits a Significant Impact on Tumor Angiogenesis, Progression, and Metastasis in Clear Cell Renal Cell Carcinoma (ccRCC)

Ferician

Neşiu

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, the urinary common rejection module (uCRM) score was also found to be elevated in other kidney injuries, such as acute tubular necrosis and BK virus nephropathy (BKVN) [163]. Overall, as is the case for emerging biomarkers in contemporary renal oncology [164][165][166][167][168][169], while numerous potential AR biomarkers have been identified through the plethora of recent studies published, their specificity and sensitivity in clinical practice remains to be determined. For instance, ddcfDNA has been found to be increased in confirmed AR cases [138], yet it is also present in other kidney injuries, such as pyelonephritis, making it less specific as a marker for AR [170].…”

Section: Genomic Evidencementioning

confidence: 99%

Contemporary Biomarkers for Renal Transplantation: A Narrative Overview

Novacescu,

Latcu,

Bardan

et al. 2023

JPM

View full text Add to dashboard Cite

Renal transplantation (RT) is the preferred treatment for end-stage renal disease. However, clinical challenges persist, i.e., early detection of graft dysfunction, timely identification of rejection episodes, personalization of immunosuppressive therapy, and prediction of long-term graft survival. Biomarkers have emerged as valuable tools to address these challenges and revolutionize RT patient care. Our review synthesizes the existing scientific literature to highlight promising biomarkers, their biological characteristics, and their potential roles in enhancing clinical decision-making and patient outcomes. Emerging non-invasive biomarkers seemingly provide valuable insights into the immunopathology of nephron injury and allograft rejection. Moreover, we analyzed biomarkers with intra-nephron specificities, i.e., glomerular vs. tubular (proximal vs. distal), which can localize an injury in different nephron areas. Additionally, this paper provides a comprehensive analysis of the potential clinical applications of biomarkers in the prediction, detection, differential diagnosis and assessment of post-RT non-surgical allograft complications. Lastly, we focus on the pursuit of immune tolerance biomarkers, which aims to reclassify transplant recipients based on immune risk thresholds, guide personalized immunosuppression strategies, and ultimately identify patients for whom immunosuppression may safely be reduced. Further research, validation, standardization, and prospective studies are necessary to fully harness the clinical utility of RT biomarkers and guide the development of targeted therapies.

show abstract

“…Immunohistochemistry (IHC) is a vital part of the routine pathological evaluation of kidney tumors [ 9 , 10 , 11 , 12 ], and RCCs in particular. Recent developments have provided a wide variety of potentially relevant RCC-associated proteomic targets [ 8 , 13 , 14 , 15 ]. However, herein there are substantial limitations, i.e., retrospective designs, limited samples, inconsistent clinical data, and an overall lack of standardization, with implicit extensive data heterogeneity [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy Applications for Thymine Dimers and WT1 Antigen in Renal Cancers: A Comparative Statistical Analysis

Latcu,

Bardan,

Cumpanas

et al. 2024

JPM

Self Cite

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) remains incurable in advanced stages. Biomarkers have proven to be quite useful in cancer therapeutics. Herein, we provide a comparative/integrative statistical analysis of seminal immunohistochemistry (IHC) findings for Wilms’ Tumor 1 antigen (WT1) and thymine dimers (TDs), emerging as atypical, yet promising, potential biomarkers for RCCs. We assessed WT1/TD reactivity in adult RCC tumor cells, tumor microenvironment (TME), and tumor-adjacent healthy renal tissue (HRT). WT1 positivity was scarce and strictly nuclear in tumor cells, whereas TD-reactive tumor tissues were prevalent. We report statistically significant positive correlations between the density of reactive RCC cellularity and the intensity of nuclear staining for both biomarkers (WT1 − rho = 0.341, p-value = 0.036; TDs − rho = 0.379, p-value = 0.002). RCC stromal TME TD-positivity was much more frequent than WT1 reactivity, apparently proportional to that of the proper RCC cellularity and facilitated by extensive RCC inflammatory infiltration. TDs exhibited nuclear reactivity for most TME cell lines, while RCC TME WT1 expression was rare and inconsistent. In HRTs, TDs were entirely restricted to renal tubular cells, the likely cellular progenitor of most conventional RCC subtypes. In lieu of proper validation, these early findings have significant implications regarding the origins/biology of RCCs and may inform RCC therapeutics, both accounting for the high frequency of immunotherapy-permissive frameshift indels in RCCs, but also hinting at novel predictive clinical tools for WT1-targeted immunotherapy. Overall, the current study represents a meek yet hopefully significant step towards understanding the molecular biology and potential therapeutic targets of RCCs.

show abstract

Anti-chloride Intracellular Channel Protein 1 (CLIC1) Antibodies Induce Tumour Necrosis and Angiogenesis Inhibition onIn VivoExperimental Models of Human Renal Cancer

Cited by 4 publications

References 0 publications

The Mutually Mediated Chloride Intracellular Channel Protein 1 (CLIC1) Relationship between Malignant Cells and Tumor Blood Vessel Endothelium Exhibits a Significant Impact on Tumor Angiogenesis, Progression, and Metastasis in Clear Cell Renal Cell Carcinoma (ccRCC)

The Mutually Mediated Chloride Intracellular Channel Protein 1 (CLIC1) Relationship between Malignant Cells and Tumor Blood Vessel Endothelium Exhibits a Significant Impact on Tumor Angiogenesis, Progression, and Metastasis in Clear Cell Renal Cell Carcinoma (ccRCC)

Contemporary Biomarkers for Renal Transplantation: A Narrative Overview

Immunotherapy Applications for Thymine Dimers and WT1 Antigen in Renal Cancers: A Comparative Statistical Analysis

Contact Info

Product

Resources

About